https://pubmed.ncbi.nlm.nih.gov/34655839/?dopt=Abstract
Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600...
Triplet therapy with PEM, ENC and BIN as used in the study was feasible and safe and led to clinically meaningful disease control.
in patientsencorafenibbinimetinibpluspembrolizumab
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2013.00346/full
Frontiers | Impact of MAPK Pathway Activation in BRAFV600 Melanoma on T Cell and Dendritic Cell...
Constitutive upregulation of the MAPK pathway by a BRAFV600 mutation occurs in about half of melanomas. This leads to increased oncogenic properties such as...